Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services. by Nglazi, Mweete Debra et al.
Nglazi, MD; Kaplan, R; Caldwell, J; Peton, N; Lawn, SD; Wood,
R; Bekker, LG (2012) Antiretroviral treatment uptake in patients
with HIV-associated TB attending co-located TB and ART services.
South African Medical Journal, 102 (12). pp. 936-9. ISSN 0256-9574
DOI: https://doi.org/10.7196/samj.6024
Downloaded from: http://researchonline.lshtm.ac.uk/2043793/
DOI: 10.7196/samj.6024
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/3.0/
RESEARCH
936  December 2012, Vol. 102, No. 12  SAMJ
South Africa has a high burden of both TB and HIV1-3 and a high HIV-
associated TB case fatality rate.4 Optimal case management of HIV-
associated TB requires standardised anti-TB treatment combined with 
trimethoprim-sulphamethoxazole (co-trimoxazole) prophylaxis and 
antiretroviral treatment (ART). ART results in a 64 - 95% reduction in 
mortality risk 5 and is an essential component of care. How soon to start 
ART after TB treatment initiation has become clearer from randomised 
controlled trials. These show that integration of ART and TB treatment 
in all HIV-associated TB patients regardless of CD4 count significantly 
improves survival,6 and that early ART (within 2 weeks of starting TB 
treatment) was particularly beneficial for patients with CD4 counts <50 
cells/µl.7-9 These data support the World Health Organization (WHO) 
ART 2010 guidelines that recommend ART is started within 2 - 8 
weeks of starting TB treatment.10
Although the guidelines recommending the optimal time to start 
ART in patients with HIV-associated TB have been established, the 
delivery of integrated care for these patients remains challenging. 
Models of integrated care in resource-limited countries include: efficient 
referrals between separately located TB and ART clinics; provision of 
TB and ART services on the same premises but by different service 
teams; and fully combined services with provision of TB treatment and 
ART from the same staff.11,12 The goal is to provide streamlined care, 
minimise patient losses and ensure timely initiation of ART.
Few data exist on patient losses from care and delays in starting ART 
among HIV-associated TB patients at different stages in the cascade 
between HIV-associated TB diagnosis and ART initiation in a variety 
of models of integrated care.13-18 Delivery of care in South Africa has 
largely been based within completely separate TB and ART services. 
In a primary care setting in a Cape Town township, we piloted delivery 
of care using co-located services in the same facility. We conducted 
this retrospective observational cohort study to assess the uptake and 
timing of ART initiation and losses from the care pathway.
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Background. Delivery of integrated care for patients with HIV-associated TB is challenging. We assessed the uptake and timing of 
antiretroviral treatment (ART) among eligible patients attending a primary care service with co-located ART and TB clinics.
Methods. In a retrospective cohort study, all HIV-associated TB patients (≥18 years old) who commenced TB treatment in 2010 were 
included. Data were analysed using basic descriptive statistics and log-binomial regression analysis.
Results. Of a total of 497 patients diagnosed with HIV-associated TB, 274 were eligible to start ART for the first time (median CD4 count, 
159 cells/µl). ART was started during TB treatment by 220 (80.3%) patients. Among the 54 (19.7%) who did not start ART, 23 (42.6%) were 
either lost to follow-up (LTFU) or died before enrolling for ART; 12 (22.2%) were either LTFU or died after enrolling but before starting 
ART; 5 (9.3%) were transferred out; and 14 (25.9%) only started ART after completion of TB treatment. The median delay between starting 
TB treatment and starting ART was 51 days (IQR 29 - 77). Overall, only 58.6% of patients started ART within 8 weeks of TB treatment, and 
12.7% of those with CD4 counts <50 cells/µl started ART within 2 weeks.
Conclusions. In a setting with co-located TB and ART clinics, delays to starting ART were substantial, and one-fifth of eligible patients did 
not start ART during TB treatment. Co-location of services alone is insufficient to permit timely initiation of ART; further measures need 
to be implemented to facilitate integrated treatment.
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Methods
Setting
The study was conducted at Nyanga Community Health Centre (CHC), 
Klipfontein health sub-district, Cape Town. An estimated 420 000 
people19 live in this predominantly low-income urban community, 
which had an antenatal HIV-1 prevalence rate of 24% in 2009.20 This 
nurse-run, doctor-supported service has provided TB and ART care for 
patients since 2008. Here, TB treatment and ART is delivered by separate 
health authorities but located in the same building. Most ART-eligible 
co-infected patients receiving TB treatment at the TB clinic were referred 
to the ART clinic at the same site, and a minority were transferred-out to 
separate ART clinics in different localities in Cape Town.
The clinic staff at the TB service followed the South African National 
TB guidelines21 for TB case detection, notification and treatment. TB 
was treated using standardised rifampicin-based regimens of 6 months’ 
duration for new TB cases and 8 months for retreatment cases. During 
the study period, the South African ART guidelines were revised: 
before April 2010, staff at both TB and ART services followed the 2004 
South African ART guidelines which recommended that patients with 
CD4 counts of 50 - 200 cells/µl should delay ART until after 2 months 
of starting TB treatment, while those with a CD4 count <50 cells/µl or 
with serious co-morbidities should commence ART as soon as possible 
after at least 2 weeks of TB treatment.22 After April 2010, the clinic staff 
were advised to adopt the 2010 South African ART guidelines, which 
recommended that TB patients with CD4 cell counts <100 cells/µl or 
WHO stage IV should commence ART within 2 weeks of eligibility, 
and those with CD4 cell counts ≤350 cells/µl should commence ART 
within 2 - 8 weeks of starting TB treatment.23
Data sources
The following data sources were used: (i) Western Cape’s electronic 
eKapa TB and ART database which is currently being used at this 
clinic. TB data in this database have been prospectively maintained 
since October 2009, including demographic and clinical information 
on TB patients and on TB treatment visits and outcomes per TB 
episode. HIV data have been prospectively maintained since March 
2007, including demographic data and clinical data on patients’ ART 
treatment visits and outcomes. Both HIV and TB episodes are linked 
to patients using a unique identifier; (ii) paper-based TB register and 
the Western Cape’s electronic TB register (ETR.net) which monitors 
TB treatment; (iii) National Health Laboratory Services (NHLS) 
database; and (iv) patient records.
Data collection
All HIV-associated TB patients ≥18 years old who were registered and 
commenced on TB treatment between January 2010 and December 
2010 were included. The Western Cape electronic data collection 
system, eKapa was used to obtain information on demographic 
characteristics (age and gender), clinical characteristics (TB disease 
classification, CD4 count and patient category) and TB treatment-
related variables (date of starting TB treatment and regimen received). 
Information was also obtained on the uptake of ART and the time of 
ART initiation during TB treatment. Where information was missing, 
it was sought from patient records, NHLS database, paper based 
and electronic TB registers. Ethical clearance for the collection of 
routine data was obtained from the Research Ethics Committees of 
the University of Cape Town and the International Union against 
Tuberculosis and Lung Disease.
Definitions
Pre ART losses refer to failure to reach the next step in the care 
cascade from starting TB treatment  to starting ART as a result of 
death and loss to follow-up (LTFU). Transfer to another TB and 
ART service was not regarded as a loss — patients who transfer are 
assumed to be retained.
Death refers to all-cause mortality.
Lost to follow-up refers to: (i) HIV-associated TB patients 
registered at the TB service who defaulted TB treatment for ≥8 weeks 
and failed to enrol in the ART service; (ii) HIV-associated TB patients 
who enrolled in the ART service but failed to attend the ART service 
for ≥12 weeks before starting ART; and (iii) patients classified as 
LTFU who were not known to have died or transferred to another 
facility.
ART eligibility was defined according to the South African 
national ART guidelines.22,23
Statistical analyses
Statistical analyses were performed using STATA statistical software, 
version 11.0 (STATA Corporation, College Station, Texas, USA). 
Basic descriptive statistics were used to characterise uptake of 
ART (using proportions) and timing of ART during TB treatment 
(using median and interquartile ranges). Proportions of patients 
who started ART within specific time points were calculated and 
stratified by CD4 count. The CD4 count strata were categorized as 
<50 cells/µl, and 50 - 200 cells/µl and 200 - 350 cells/µl according to 
the recent recommendations and guidelines.7-9,22,23 The time intervals 
considered were ART commencement between 2 and 8 weeks, and 
we determined the risk factors associated with starting ART after 
more than 8 weeks of TB treatment using log-binomial regression 
analysis.
Results
Patient characteristics
A total of 784 patients ≥18 years started TB treatment from January 
- December 2010 (Fig. 1). Of these, 10 had unknown HIV status, 
277 were HIV-negative and 497 were HIV-positive. Among the 
497 patients diagnosed with HIV-associated TB, 130 were already 
receiving ART at the time of diagnosis (Fig. 1). Of the 367 not 
yet on ART at the time of TB diagnosis, 363 had CD4 cell count 
information available. Because the South African ART guidelines 
were revised during the study period, ART eligibility was assessed 
using CD4 cell counts <200 cells/µl prior to April 2010, and CD4 
cells counts ≤350 cells/µl after April 2010. Overall, 274 were ART 
eligible and therefore formed the patient cohort of this study that 
was followed up to determine if ART was initiated appropriately 
during TB treatment.
The patient cohort (N=274) characteristics at the time of start of 
TB treatment were: 51.8% of HIV-associated TB patients were female 
and of median age 34 years (interquartile range (IQR) 29 - 38) (Table 
1). Immunodeficiency was advanced with a median blood CD4 
lymphocyte count of 158.5 cells/µl (IQR 69 - 303); 73.4% co-infected 
patients had a new diagnosis of TB, and the majority of 194 (70.8%) 
were diagnosed as pulmonary TB of whom 50.0% were confirmed 
smear-negative TB (99/194).
Uptake of antiretroviral treatment
Of the 274 HIV-associated TB patients who were eligible to start 
ART for the first time (median CD4 count, 158.5 cells/µl), ART was 
started during TB treatment by 220 (80.3%) patients; 54 (19.7%) did 
not start ART (Fig. 1). Among the patients who did not start ART, 23 
(42.6%) were LTFU or died prior to enrolment for ART; 12 (22.2%) 
were LTFU or died after enrolment but prior to starting ART; 5 
(9.3%) were transferred-out; and 14 (25.9%) only started ART after 
completion of TB treatment.
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Deaths
Among the 54 patients who did not start ART, 15 (27.8%). patients 
died; 13 died before enrolment for ART and 2 died after enrolment 
but prior to starting ART; 6 (40%) of the 15 patients who died had 
CD4 cell counts <50 cells/µl.
Time delays in starting antiretroviral treatment
Among the 220 known to have started ART during TB treatment, 215 
had ART initiation dates recorded in patient records. Of these, the 
overall median time delay between starting TB treatment and starting 
ART was was 51 days (IQR 29 - 77). Because of the survival benefit of 
starting within 2 weeks of TB treatment in patients with CD4 counts 
<50 cells/µl and the national ART guideline reccommedation to start 
ART within 8 weeks for those with CD4 counts <350 cells/µl, we 
examined delays in starting ART stratified by CD4 cell count. Among 
those with CD4 counts <50 cells/µl, we found that only 12.7% (7/55) 
of them had started ART within 2 weeks (Table 2). In those with CD4 
counts of 50 - 350 cells/µl, 53.1% (85/160) started ART within 8 weeks.
Risk factors associated with starting ART after 8 weeks 
of TB treatment
We used univariate and multivariate analyses to determine the factors 
associated with starting ART after 8 weeks of TB treatment. Univariate 
analyses showed that patients with reccurrent TB were 2.4 times (95% 
confidence interval (CI) 1.28 - 4.49) more likey to start ART after 8 
weeks of TB treatment than those with new TB. The risk for starting 
ART after 8 weeks of TB treatment was higher among patients with 
CD4 cell counts of 50 - 200 cells/µl (risk ratio (RR) 2.29; 95% CI 1.12 - 
4.66) and those with CD4 cell counts of 200 - 350 cells/µl (RR 3.49; 95% 
CI 1.51 - 8.07) compared with those with CD4 cell counts <50 cells/µl. 
Multivariate analyses showed similar results.
Discussion
In this study, we assessed the proportion of HIV-associated TB patients 
who successfully started ART and the timing of ART initiation during 
TB treatment. Of eligible patients, 19.7% (54/274) did not start ART. 
However, there were losses in the cascade from ART eligibility to ART 
initiation. Of eligible patients who did not start ART, 42.6% (23/54) were 
LTFU or died before enrolment for ART, and 22.2% (12/54) were LTFU 
or died after enrolment but prior to starting ART. The delay in starting 
ART was substantial (51 days) and exceeded the recommendations of 
the 2010 WHO and national ART guidelines,10,23 especially for patients 
Fig. 1. Flow diagram showing uptake of ART treatment among HIV-
associated TB patients. ART eligibility according to South African ART 
guidelines.22,23
Table 2. Duration of delays between starting TB treatment and starting ART among patients who initiated treatment with ART start 
date recorded and stratified by CD4 cell count category
Duration of delay between 
starting TB treatment and 
starting ART
Patients with CD4 
<50 cells/µl (n=55)
Patients with CD4
50 - 200 cells/µl (n=114)
Patients with CD4
 >200 cells/µl (n=46) All patients (N=215)
<2 weeks 7 (12.7) 6 (5.3) 2 (4.4) 15 (6.9)
<4 weeks 20 (36.4) 25 (21.9) 8 (17.4) 53 (24.7)
<6 weeks 30 (54.6) 46 (40.4) 11 (23.9) 87 (40.5)
<8 weeks 41 (74.6) 64 (56.1) 21 (45.7) 126 (58.6)
>8 weeks 14 (25.5) 50 (43.9) 25 (54.4) 89 (41.4)
Table 1. Baseline characteristics for TB/HIV co-infected ART-
eligible patients ≥18 years old who started TB treatment in 2010
Variables N=274
Age, years
18 - 35 171 (62.4)
≥36 103 (37.6)
Gender
Female 142 (51.8)
Male 132 (48.1)
Patient category
New 201 (73.4)
Retreatment 73 (26.6)
Type of TB*
Smear-negative PTB 99 (36.1)
Smear-positive PTB 95 (34.7)
EPTB 80 (29.2)
CD4 count, cells/µl
<50 68 (24.8)
50 - 200 140 (51.1)
>200 66 (24.1)
TB regimen
Regimen 1 200 (73.0)
Regimen 2 74 (27.0)
PTB = pulmonary TB; EPTB = extra-pulmonary TB.
*Patients with no smears and having pulmonary TB were categorised as smear-negative 
pulmonary TB. Patients having both pulmonary and extra-pulmonary TB were categorised 
as having extra-pulmonary TB.
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with CD4 cell counts <50 cells/µl. Therefore, despite co-locating TB and 
ART services, there are substantial delays in starting ART during TB 
treatment, and some patients did not start ART at all.
Our finding that 20% of eligible patients did not start ART lies within 
the range reported elsewhere in sub-Saharan Africa providing either 
separate or fully integrated services, of proportions of 13 - 86%,13,14,16,17 
which shows that there are barriers to successful uptake of ART regardless 
of the model of care applied, and further measures must be implemented 
to facilitate efficient treatment integration. Of those not starting ART, 
42.6% had died or were LTFU before enrolment for ART, and 20% of 
them died or were LTFU after enrolment but prior to starting ART. 
These data clearly indicate that retention in the stage in the cascade from 
ART eligibility to ART initiation must be improved. Retention might be 
improved by allowing ART services to dispense TB treatment and vice 
versa to streamline appointments and reduce duplication of services. 
Owing to the retrospective design of the study, the reasons for the reported 
losses are unknown. Possible reasons may include stigma, fear, lack of 
time to attend the clinic especially among those who work, and lack of 
transport money for additional clinic appointments.16,24 These factors 
might also have been induced by the presence of two health authorities 
rendering either TB or ART services that were not harmonised owing to 
organisational differences. Successful integration of TB and ART services 
may require integration at all levels in the health system from clinical care 
to community support and administrative structures.
We found an overall median delay in starting ART of 51 days, which 
is within the range of sub-Saharan Africa programmes providing 
either separate or fully integrated TB and ART services, of median 
delays between 44 and 110 days.14-17 While this median falls within 
the recommended 56 day cut-off, these patients have advanced HIV 
and more must be done within health systems to ensure earlier ART 
commencement. In particular, patients most at risk of AIDS mortality 
(CD4 counts <50 cells/µl) should be fast-tracked for ART; this may 
only be achieved if ART is prescribed and administered by the TB 
services.
The association between greater delays and higher CD4 cell counts 
is similar to a study16 among patients accessing separate TB and 
ART services in Cape Town, and is in keeping with the clinical 
recommendation that severely immunocompromised patients should be 
prioritised to initiate ART as soon as possible after starting TB treatment.
The strengths of this study include the tracking of losses at each 
stage in the cascade from start of TB treatment to start of ART, and 
time delays between starting TB treatment and starting ART in distinct 
services in this single primary health clinic. It provides an understanding 
of the strengths and limitations of an alternative model of TB and ART 
services and the importance of geographically co-locating these services, 
although not necessarily combining the services.
The study limitations are that there is no direct comparison with 
alternative models of either geographically separate or fully combined 
services; only one clinic with a relatively small sample size is considered, 
and the study does not quantify component delays associated with each 
step of the cascade from start of TB treatment to ART initiation. The 
retrospective design of the study does not enable us to determine the 
reasons for pre-ART losses among co-infected patients. Lastly, the uptake 
of ART among ineligible patients is unknown. Future studies will have to 
determine what happened to ART-ineligible patients.
Conclusions
ART services were included on the same premises that provided TB 
services at this primary health clinic in the hope of reducing delays in 
starting ART and improving ART uptake. However, this study found 
delays to starting ART were substantial, and a fifth of eligible patients 
did not start ART at all. These data show that the co-location of services 
alone is insufficient to permit timely initiation of ART, and further 
measures must be implemented to facilitate integrated treatment.
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